Ahhhhhh FUTU. Another stoney double. I'm glad it crashed today!>>>>>>>>>
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Van I sit here with both ears clogged now. That new fangled machine they are running a commercial on TV it drives me crazy. What's funny is the guys sells it by saying " oooo it feels so good.."
I can tell you the experience does not " feel really good "
I can tell you the experience does not " feel really good "
Novavax, Inc. (NVAX) --- Last Call!!! Last call..........
NasdaqGS - NasdaqGS Real Time Price.
10.11+0.39 (+4.01%)
As of 12:25PM EST.
NasdaqGS - NasdaqGS Real Time Price.
10.11+0.39 (+4.01%)
As of 12:25PM EST.
Lets move up the buy and do it here---
Ardelyx, Inc. (ARDX)
NasdaqGM - NasdaqGM Real Time Price.
2.66 (+5.3360%)<--------------GO TIME-!
As of 12:32PM EST.
TED-!
Waterdrop falls -10.1% 12:00 WDH Waterdrop is down -10.1%, or -34c to $3.02.
Waterdrop falls -10.1% 12:00 WDH Waterdrop is down -10.1%, or -34c to $3.02.
Did it hit $3? Only on GBA!
Borr Drilling Limited (BORR) Setting up nice here //
NYSE - Nasdaq Real Time Price.
5.14+0.22 (+4.36%)<------------ I would buy this name is sexy like NINE- It moves.
As of 12:47PM EST. //
NYSE - Nasdaq Real Time Price.
5.14+0.22 (+4.36%)<------------ I would buy this name is sexy like NINE- It moves.
As of 12:47PM EST. //
I go to Dr soon. Leave you with this--
So ARDX-- It got a rare reversal by the FDA... they will now be able to submit...
This has set off a lot of debate.. Most analysts are hype on thei dea now....
Show Full Stories Send Info
Citi ups Ardelyx target, sees approval odds 'nearly 100%' 16:04
ARDX
Citi analyst Yigal Nochomovitz raised the firm's price target on Ardelyx to $7 from $6 and keeps a Buy rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. The analyst does not believe the market is "appropriately absorbing the magnitude of this unprecedented regulatory reversal." The hat the Complete Response Letter has been formally overturned and the probability of approval in 2023 is "nearly 100%," Nochomovitz tells investors in a research note. As such, the analyst raised Xphozah's probability of success for Xphozah to 97.5%.
Ardelyx approval for tenapanor 'still far from a slam dunk,' says Wedbush 10:12
ARDX
After Ardelyx disclosed that FDA's Office of New Drugs has issued an Appeal Granted Letter in its formal dispute resolution request after the company previously received a Complete Response Letter for tenapanor in hyperphosphatemia, Wedbush analyst Laura Chico said there are more regulatory hurdles to cross. While this opens a path forward for tenapanor and represents "a much-needed win" for Ardelyx, approval is "still far from a slam dunk," Chico tells investors. She awaits greater clarity on potential labeling and populations before layering in the tenapanor in hyperphosphatemia opportunity to her estimates and maintains a Neutral rating on Ardelyx shares with a $2 price target.
Ardelyx price target raised to $3 from $1.60 at Cantor Fitzgerald 10:03
ARDX
Cantor Fitzgerald analyst Louise Chen raised the firm's price target on Ardelyx to $3 from $1.60 and keeps a Neutral rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. This is "clearly good news for the company," Chen tells investors in a research note. However, the analyst remains on the sidelines pending greater earnings visibility in 2023 and beyond.
Show Related Items >>
Ardelyx approval odds 'very high' after FDA grants appeal, says Piper 10:00
ARDX
Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Ardelyx with an $8 price target after the FDA granted the appeal to the Complete Response Letter for Xphozah. The appeal grant comes with FDA's direction for the company to work with the Division of Cardiology and Nephrology to develop an appropriate label, which the company believes could be directed at patients whose hyperphosphatemia is insufficiently managed on phosphate binders, Raymond tells investors in a research note. He believes the likelihood of Xphozah getting approved are "very high after today's decision." Raymond continues to like the stock's risk/reward, saying it is "heavily positively skewed at this point." Shares of Ardelyx are down 11% to $2.33 in early trading.
So ARDX-- It got a rare reversal by the FDA... they will now be able to submit...
This has set off a lot of debate.. Most analysts are hype on thei dea now....
Show Full Stories Send Info
Citi ups Ardelyx target, sees approval odds 'nearly 100%' 16:04
ARDX
Citi analyst Yigal Nochomovitz raised the firm's price target on Ardelyx to $7 from $6 and keeps a Buy rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. The analyst does not believe the market is "appropriately absorbing the magnitude of this unprecedented regulatory reversal." The hat the Complete Response Letter has been formally overturned and the probability of approval in 2023 is "nearly 100%," Nochomovitz tells investors in a research note. As such, the analyst raised Xphozah's probability of success for Xphozah to 97.5%.
Ardelyx approval for tenapanor 'still far from a slam dunk,' says Wedbush 10:12
ARDX
After Ardelyx disclosed that FDA's Office of New Drugs has issued an Appeal Granted Letter in its formal dispute resolution request after the company previously received a Complete Response Letter for tenapanor in hyperphosphatemia, Wedbush analyst Laura Chico said there are more regulatory hurdles to cross. While this opens a path forward for tenapanor and represents "a much-needed win" for Ardelyx, approval is "still far from a slam dunk," Chico tells investors. She awaits greater clarity on potential labeling and populations before layering in the tenapanor in hyperphosphatemia opportunity to her estimates and maintains a Neutral rating on Ardelyx shares with a $2 price target.
Ardelyx price target raised to $3 from $1.60 at Cantor Fitzgerald 10:03
ARDX
Cantor Fitzgerald analyst Louise Chen raised the firm's price target on Ardelyx to $3 from $1.60 and keeps a Neutral rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. This is "clearly good news for the company," Chen tells investors in a research note. However, the analyst remains on the sidelines pending greater earnings visibility in 2023 and beyond.
Show Related Items >>
Ardelyx approval odds 'very high' after FDA grants appeal, says Piper 10:00
ARDX
Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Ardelyx with an $8 price target after the FDA granted the appeal to the Complete Response Letter for Xphozah. The appeal grant comes with FDA's direction for the company to work with the Division of Cardiology and Nephrology to develop an appropriate label, which the company believes could be directed at patients whose hyperphosphatemia is insufficiently managed on phosphate binders, Raymond tells investors in a research note. He believes the likelihood of Xphozah getting approved are "very high after today's decision." Raymond continues to like the stock's risk/reward, saying it is "heavily positively skewed at this point." Shares of Ardelyx are down 11% to $2.33 in early trading.